A detailed history of Daiwa Securities Group Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 3,894 shares of PCVX stock, worth $436,517. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,894
Previous 3,898 0.1%
Holding current value
$436,517
Previous $266,000 10.53%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$60.06 - $78.77 $240 - $315
-4 Reduced 0.1%
3,894 $294,000
Q1 2024

May 02, 2024

BUY
$59.79 - $81.05 $717 - $972
12 Added 0.31%
3,898 $266,000
Q4 2023

Jan 31, 2024

BUY
$45.35 - $63.41 $161,808 - $226,246
3,568 Added 1122.01%
3,886 $244,000
Q4 2022

Feb 06, 2023

BUY
$20.58 - $47.95 $2,860 - $6,665
139 Added 77.65%
318 $15,000
Q3 2021

Nov 05, 2021

BUY
$20.26 - $26.97 $1,681 - $2,238
83 Added 86.46%
179 $5,000
Q4 2020

Feb 04, 2021

BUY
$26.57 - $51.74 $2,550 - $4,967
96 New
96 $3,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $6.65B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.